Delving into Acromegaly

Störmann, Sylvère; Schilbach, Katharina

doi:10.3390/jcm12041654

Cited by 2 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lactotroph Pharmacologic (DA) [11] TSS [12][13] RT [14] Somatotroph TSS [15] Pharmacologic [16] RT [14] Corticotroph TSS [17] Pharmacologic (adrenal enzyme inhibitors, adrenolytic agents, or glucocorticoid-receptor antagonists) [19] RT [14] Bilateral total adrenalectomy (may be preferred by the patient) * [20] RT (for children under age 18 years) * [18] Thyrotroph TSS Pharmacologic (somatostatin analogues) [22] RT [23] Pharmacologic before surgery to restore euthyroidism (somatostatin analogues) * [21] Gonadotroph TSS [24] RT [25] -Non-functioning TSS [24] RT [25] -…”

Section: Adenoma Type First Line [Ref] Second Line [Ref] Third Line [...mentioning

confidence: 99%

Metabolic Syndrome Components in Patients with Pituitary Adenoma

Gonzalez-Almazan,

Cortes-Contreras,

Flores-Rabasa

et al. 2023

Horm Metab Res

View full text Add to dashboard Cite

Pituitary adenomas are benign tumors of the anterior portion of the pituitary gland (adenohypophysis), representing the 25% of all the tumor alterations. Pituitary adenomas are classified by the type of hormone secreted, cellularity, size, and structural alterations by the hormonal segregation. The diagnosis consists on the histopathological identification of cell types and the image-guided by magnetic resonance or tomography; the treatment can be both pharmacological and surgical. Metabolic Syndrome is the set of clinical conditions that increase the risk of cardiovascular diseases with an estimated prevalence of 25% worldwide. The alterations of metabolic syndrome are obesity, hypertension, dyslipidemia, insulin resistance, and diabetes mellitus type II. Pituitary adenomas and metabolic syndrome have an important relationship, hormone-secreting by pituitary adenomas affects a myriad of signaling pathways, which allows a favorable environment for the appearance of the metabolic syndrome. Moreover, patients with pituitary adenomas are shown to have an improvement in metabolic parameters after the medical/surgical treatment. The objective of this review is to explore the possible mechanisms through which PAs contributes to MetSx.

show abstract

Section: Adenoma Type First Line [Ref] Second Line [Ref] Third Line [...mentioning

confidence: 99%

Metabolic Syndrome Components in Patients with Pituitary Adenoma

Gonzalez-Almazan,

Cortes-Contreras,

Flores-Rabasa

et al. 2023

Horm Metab Res

View full text Add to dashboard Cite

show abstract

“…The majority of GH-secreting pituitary tumors are benign, although some tumors may present with aggressive features and have a high risk of recurrence after surgical treatment ( 3 ). Persistently high levels of GH and/or IGF-1 can lead to comorbidities of the cardiovascular, respiratory, bone, and endocrine systems, and are associated with increased mortality rates ( 2 , 4 , 5 ). Therefore, normalizing GH and/or IGF-1 levels is a critical treatment goal for acromegaly patients.…”

Section: Introductionmentioning

confidence: 99%

Using 2-dimensional hand photographs to predict postoperative biochemical remission in acromegaly patients: a transfer learning approach

Wang¹,

Duan²,

Yao³

et al. 2023

Quant Imaging Med Surg

View full text Add to dashboard Cite

Background The primary treatment goals in acromegaly patients are complete surgical removal of underlying pituitary tumors and biochemical remission. One of the challenges in developing countries is the difficulty in monitoring postoperative biochemical levels in acromegaly patients, particularly those who live in remote areas or regions with limited medical resources. Methods In an attempt to overcome the abovementioned challenges, we conducted a retrospective study and established a mobile and low-cost method to predict biochemical remission in acromegaly patients after surgery, the efficacy of which was assessed retrospectively using the China Acromegaly Patient Association (CAPA) database. A total of 368 surgical patients from the CAPA database were successfully followed up to obtain their hand photographs. Demographics, baseline clinical characteristics, pituitary tumor features, and treatment details were collated. Postoperative outcome, defined as biochemical remission at the last follow-up timepoint, was assessed. Transfer learning with a new mobile tailored neurocomputing architecture, MobileNetv2, was used to explore the identical features that could be used as predictors of long-term biochemical remission after surgery. Results As expected, the MobileNetv2-based transfer learning algorithm was shown to predict biochemical remission with statistical accuracies of 0.96 and 0.76 in the training cohort (n=803) and validation cohort (n=200), respectively, and the loss function value was 0.82. Conclusions Our findings demonstrate the potential of the MobileNetv2-based transfer learning algorithm in predicting biochemical remission for postoperative patients who are at home or live far away from a pituitary or neuroendocrinological treatment center.

show abstract

Delving into Acromegaly

Abstract: Acromegaly is a rare and disabling disease with some distinct and striking clinical features that have fascinated (and frightened) laypeople and medical experts alike throughout history [...]

Cited by 2 publications

References 24 publications

Metabolic Syndrome Components in Patients with Pituitary Adenoma

Metabolic Syndrome Components in Patients with Pituitary Adenoma

Using 2-dimensional hand photographs to predict postoperative biochemical remission in acromegaly patients: a transfer learning approach

Contact Info

Product

Resources

About